Transfer factor therapy for histoplasmosis in a patient with Hodgkin's disease.
A patient with recurrent chronic histoplasmosis was diagnosed also as having Hodgkin's disease. Studies of cell-mediated immunity (CMI) demonstrated no reaction to histoplasmin by skin test, lymphocyte transformation (LT), or leukocyte inhibition factor (LIF) assay. Clinical and immunologic studies were performed during treatment with 19 doses of dialyzable transfer factor (TF) prepared from a normal donor with strong CMI against histoplasmin. Transfer of CMI to the patient was demonstrated by all three tests. All tests reverted to nonreactive during the period of observation. Repeated doses of dialyzable TF were followed by reconversion of skin tests. The LIF assay was most reactive. Reactivation of histoplasmosis occurred during antimetabolic therapy for Hodgkin's disease; however, the lesions cleared rapidly when TF was added to amphotericin B. Amphotericin B was administered at a dosage of 25 mg three times each week during the entire study.
D000328:Adult; D002464:Cell Migration Inhibition; D002908:Chronic Disease; D006660:Histoplasmosis / Q000150:complications / Q000276:immunology / Q000628:therapy*; D006689:Hodgkin Disease / Q000150:complications* / Q000276:immunology; D006801:Humans; D007962:Leukocytes / Q000276:immunology; D008213:Lymphocyte Activation; D008297:Male; D012882:Skin Tests; D014165:Transfer Factor / Q000627:therapeutic use*
D014165:Transfer Factor